Archived Press Releases

2010

11/5/2010
Plexxikon Announces Preliminary PLX4032 Phase 2 Data Confirming Substantial Response Rate in Metastatic Melanoma Patients

9/7/2010
Plexxikon Data Shows PLX4032 Selectivity Enables Substantial Pathway Inhibition and Significant Clinical Response

8/25/2010
Plexxikon Publishes PLX4032 Phase 1 Data Demonstrating 81 Percent Response Rate in Metastatic Melanoma Patients in the New England Journal of Medicine

7/14/2010
Plexxikon's Novel Agent Significantly Inhibits Activation of Key CNS Cells Associated With Alzheimer's Disease

6/6/2010
PLX4032 Phase 1 Extension Data in Colorectal Cancer Reported

4/20/2010
Plexxikon's PLX3397 Preclinical Data Demonstrate Potential of Novel, "First-in-Class" Cancer Drug

4/19/2010
Plexxikon Co-Founder Joseph Schlessinger, Ph.D., Awarded 2010 Pezcoller Foundation-AACR International Award for Cancer Research

1/8/2010
Plexxikon Announces First Patient Dosed in Phase 3 Trial

2009

10/8/2009
Plexxikon Treats Initial Patient With First-in-Class Drug in Phase 1 Trial

9/30/2009
Plexxikon Announces First Patient Dosed in First of Two Pivotal Trials of PLX4032 for Metastatic Melanoma

9/23/2009
Plexxikon Announces Encouraging Data from Phase 1 Extension Study of PLX4032 Showing Objective Responses in Metastatic Melanoma Patients

9/10/2009
Key Data Related to Plexxikon's Lead Oncology Program PLX4032 to be Presented at ECCO15 / ESMO34 2009 Conference

6/1/2009
Plexxikon Announces PLX4032 Phase 1 Data Showing Objective Responses in Metastatic Melanoma Patients

5/15/2009
Key Data Related to Plexxikon's Lead Oncology Program PLX4032 to be Presented at ASCO 2009 Annual Meeting

3/19/2009
Plexxikon Receives Key Patents on Novel Compounds for Multiple Programs

1/8/2009
Plexxikon and Roche Enter Second Partnership to Develop PLX5568 for Polycystic Kidney Disease

 

Back to Press Releases